GlassScriptPhysician profile
Layne Lemaire
NPI 1235554791
$12,908.22
in general payments reported to CMS, 2019-2025
50 companies · $3,055 in 2025
The $3,055 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,041 · 2022: $2,682 · 2023: $2,262 · 2024: $2,869 · 2025: $3,055.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,982 · Education: $204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,981.77 |
| Education | $203.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,255.10 | 2021-2025 | Otezla, Enbrel, Tavneos |
| Abbvie INC. | $1,903.97 | 2021-2025 | |
| Ucb, INC. | $908.60 | 2021-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $832.37 | 2021-2025 | Tremfya, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $659.63 | 2021-2025 | |
| Radius Health, INC. | $457.49 | 2021-2025 | Tymlos |
| Aurinia Pharma U.S., INC. | $440.16 | 2021-2025 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $415.11 | 2022-2025 | Ofev, Spevigo, Jardiance |
| Genzyme Corporation | $329.71 | 2021-2025 | |
| Corcept Therapeutics | $260.78 | 2021-2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $255.29 | 2021-2025 | Saphnelo |
| Genentech USA, INC. | $243.34 | 2021-2023 | Actemra |
| Ani Pharmaceuticals, INC. | $225.92 | 2022-2025 | Purified Cortrophin Gel |
| Glaxosmithkline, LLC. | $203.85 | 2021-2024 | Benlysta |
| Insulet Corporation | $194.38 | 2023-2025 | Omnipod |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $190.77 | 2021-2025 | Ozempic |
| Xeris Pharmaceuticals, INC. | $188.96 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Sobi, INC | $184.60 | 2022-2025 | |
| Recordati_rare_diseases_inc. | $166.24 | 2021-2025 | Isturisa, Signifor Lar |
| Lilly USA, LLC | $146.34 | 2021-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $136.44 | 2021-2023 | Steglatro, Steglujan, Segluromet |
| E.R. Squibb & Sons, L.L.C. | $127.76 | 2024-2025 | Orencia |
| Mallinckrodt Hospital Products INC. | $113.01 | 2021-2025 | Acthar |
| Beta Bionics, INC. | $99.13 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Alexion Pharmaceuticals, INC. | $93.18 | 2021-2025 | Strensiq |
| Medtronic, INC. | $93.10 | 2023-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Sanofi-Aventis U.S. LLC | $83.96 | 2021-2025 | |
| Pfizer INC. | $77.55 | 2023-2025 | |
| Fresenius Kabi USA, LLC | $66.95 | 2023 | Idacio |
| Sandoz INC. | $53.72 | 2023-2025 | Hyrimoz |
| Amarin Pharma, INC. | $50.79 | 2021-2022 | |
| Ibsa Pharma INC. | $41.68 | 2022-2024 | Licart, Flector, Tirosint |
| Organon LLC | $41.26 | 2025 | Renflexis |
| Horizon Therapeutics Plc | $38.59 | 2021-2022 | |
| Becton, Dickinson and Company | $36.41 | 2021-2022 | |
| Amryt Pharma Holdings LTD | $25.24 | 2023 | Mycapssa |
| Madrigal Pharmaceuticals | $24.12 | 2025 | Rezdiffra |
| Clarus Therapeutics INC. | $23.95 | 2021 | |
| Chiesi USA, INC. | $22.49 | 2024 | Mycapssa |
| Teva Pharmaceuticals USA, INC. | $22.44 | 2024 | Truxima |
| Takeda Pharmaceuticals U.S.A., INC. | $22.10 | 2021 | |
| Tandem Diabetes Care, INC. | $21.84 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbott Laboratories | $21.73 | 2025 | Freestyle Libre 3 |
| Acella Pharmaceuticals, LLC | $18.25 | 2023 | NP Thyroid 60 |
| Cequr Corporation | $18.17 | 2025 | Cequr Simplicity |
| Ipsen Biopharmaceuticals, INC | $17.89 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $15.84 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.87 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $13.04 | 2022 | |
| Vivus LLC | $10.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Layne Lemaire listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.